Picture Berlin Partner Hotspot for Startups 650x80px
Organisation › Details

MC2 Therapeutics A/S

MC2 Therapeutics is a privately held commercial stage pharmaceutical company committed to build leadership in topicals for autoimmune and chronic inflammatory conditions. Our focus is to develop and advance best in class or first in class therapies by understanding the pathophysiology and researching novel compounds. Our ultimate goal is to minimize the burden of disease for patients by addressing unmet needs. Using PAD™ Technology we are introducing a new standard of topical treatment experience for the benefit of patients, physicians, payers and societies. Our innovative pipeline is comprised of drug candidates within uremic pruritus, lichen sclerosis, Sjogren's syndromedry eye, ocular rosacea and atopic dermatitis. *


Period Start 2016-12-01 renamed
  Predecessor MC2 Biotek ApS
Products Industry dermatic
  Industry 2 PAD™ Technology
Person Person Lange, Jesper J. (MC2 Therapeutics 202102 CEO)
Region Region Hørsholm
  Country Denmark
  Street 24–26 Agern Allé
  City 2970 Hørsholm
  Tel +45-22-161746
    Address record changed: 2020-12-02
Basic data Employees n. a.
    * Document for �About Section�: Almirall S.A.. (2/17/21). "Press Release: Almirall and MC2 Therapeutics Enter a License, Collaboration and Commercialization Agreement for European Rights to Wynzora Cream for Treatment of Plaque Psoriasis". Barcelona & Copenhagen.
Record changed: 2021-02-23


Picture [iito] Made Without Love 650x80px

More documents for MC2 Therapeutics A/S

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Demy-Colton BioFuture 2021 NYC B Preview Download 650x300px

» top